Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

johnson & johnson (new zealand) limited - chlorhexidine gluconate 20%{relative} - topical solution - 20% w/v - active: chlorhexidine gluconate 20%{relative}

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

astrazeneca limited - sodium chloride 20%{relative} - solution for injection - 20% w/v - active: sodium chloride 20%{relative} excipient: hydrochloric acid water for injection

Reino Unido - inglés - myHealthbox

brown & burk uk ltd - lisinopril dihydrate - tablets - 2.5mg - ace inhibitor - hypertension: all grades of essential and renovascular hypertension. lisinopril tablets may be used alone or with other antihypertensives. congestive heart failure: lisinopril may be taken as an additional treatment with non-potassium-sparing diuretics and, where appropriate digoxin or digitoxin. commencement of lisinopril treatment should be under close medical supervision. severe heart failure should be treated in hospital. acute myocardial infarction: lisinopril may be used to treat haemodynamically stable patients (ie who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg). lisinopril can be given within 24 hours of acute myocardial infarction to prevent left ventricular dysfunction, heart failure, and to increase survival prospects. patients should also receive the standard recommended treatments for this condition, ie aspirin, a beta-blocker and thrombolytics.

Reino Unido - inglés - myHealthbox

brown & burk uk ltd - lisinopril dihydrate - tablets - 10mg - ace inhibitor - hypertension: all grades of essential and renovascular hypertension. lisinopril tablets may be used alone or with other antihypertensives. congestive heart failure: lisinopril may be taken as an additional treatment with nonpotassium-sparing diuretics and, where appropriate digoxin or digitoxin. commencement of lisinopril treatment should be under close medical supervision. severe heart failure should be treated in hospital. acute myocardial infarction: lisinopril may be used to treat haemodynamically stable patients (ie who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg). lisinopril can be given within 24 hours of acute myocardial infarction to prevent left ventricular dysfunction, heart failure, and to increase survival prospects. patients should also receive the standard recommended treatments for this condition, ie aspirin, a beta-blocker and thrombolytics.

Reino Unido - inglés - myHealthbox

brown & burk uk ltd - lisinopril dihydrate - tablets - 5mg - ace inhibitor - hypertension: all grades of essential and renovascular hypertension. lisinopril tablets may be used alone or with other antihypertensives. congestive heart failure: lisinopril may be taken as an additional treatment with nonpotassium-sparing diuretics and, where appropriate digoxin or digitoxin. commencement of lisinopril treatment should be under close medical supervision. severe heart failure should be treated in hospital. acute myocardial infarction: lisinopril may be used to treat haemodynamically stable patients (ie who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg). lisinopril can be given within 24 hours of acute myocardial infarction to prevent left ventricular dysfunction, heart failure, and to increase survival prospects. patients should also receive the standard recommended treatments for this condition, ie aspirin, a beta-blocker and thrombolytics.

Reino Unido - inglés - myHealthbox

brown & burk uk ltd - lisinopril dihydrate - tablets - 20mg - ace inhibitor - hypertension: all grades of essential and renovascular hypertension. lisinopril tablets may be used alone or with other antihypertensives. congestive heart failure: lisinopril may be taken as an additional treatment with nonpotassium-sparing diuretics and, where appropriate digoxin or digitoxin. commencement of lisinopril treatment should be under close medical supervision. severe heart failure should be treated in hospital. acute myocardial infarction: lisinopril may be used to treat haemodynamically stable patients (ie who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg). lisinopril can be given within 24 hours of acute myocardial infarction to prevent left ventricular dysfunction, heart failure, and to increase survival prospects. patients should also receive the standard recommended treatments for this condition, ie aspirin, a beta-blocker and thrombolytics.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - rosuvastatin calcium, quantity: 20.84 mg - tablet, film coated - excipient ingredients: lactose; crospovidone; magnesium stearate; microcrystalline cellulose; light magnesium oxide; titanium dioxide; lactose monohydrate; hypromellose; triacetin; brilliant blue fcf aluminium lake; iron oxide red; quinoline yellow aluminium lake - cavstat 20 should be used as an adjunct to diet when the response to diet and exercise is inadequate. ,prevention of cardiovascular events cavstat 20 is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). cavstat 20 is indicated to:,? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia cavstat 20 is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). ,prior to initiating therapy with cavstat 20, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - rosuvastatin calcium, quantity: 20.84 mg - tablet, film coated - excipient ingredients: lactose; microcrystalline cellulose; magnesium stearate; crospovidone; light magnesium oxide; titanium dioxide; lactose monohydrate; hypromellose; triacetin; brilliant blue fcf aluminium lake; iron oxide red; quinoline yellow aluminium lake - cavstat 20 should be used as an adjunct to diet when the response to diet and exercise is inadequate. ,prevention of cardiovascular events cavstat 20 is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). cavstat 20 is indicated to:,? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia cavstat 20 is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). ,prior to initiating therapy with cavstat 20, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Bélgica - inglés - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer sa-nv - alprostadil 20 µg/ml - powder and solvent for solution for injection - 20 µg - alprostadil 20 µg - alprostadil

Bélgica - inglés - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

curium belgium s.p.r.l.-b.v.b.a. - pentetreotide 20,8 mg - kit for radiopharmaceutical preparation - 20,8 mg - calcium trisodium diethylenetriaminepentaacetate (dtpa) 20.8 mg - technetium (99mtc) pentetic acid